David Greer, MD
Neurology · Huntsville, ALNPI 1013064815
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $43,760 of the $66,785 with a category attached, or 65.5%. It is spread thinly across 60 manufacturers, the largest accounting for just 19.2%. Among neurology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,488 payments — averaging $26.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acorda Therapeutics, Inc$13K
- Livanova USA, Inc.$7K
- AbbVie$4K
- MDD US Operations, LLC$4K
- UCB, Inc.$4K
- Novartis$2K
- plus $33K from 54 others
What the payments were for
- Consulting fees$1750%
- Speaking & faculty fees$20,00230%
- Travel & lodging$2,6264%
- Food & beverage$43,76066%
- Education$2220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INBRIJA$11,970
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$3,312
- VNS Therapy$3,122
- Xadago$2,500
- PERCEPT PC BRAINSENSE$427
- Epidiolex$385
- GOCOVRI$330
- ULTOMIRIS$175
- MAYZENT$125
- NUEDEXTA$125
- AJOVY$125
- KISUNLA$125
- VALTOCO$114
- ZEPOSIA$110
- AIMOVIG$108
How this compares
$66,785 in reported general payments places this provider in the 90th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 94 | $1,669,764 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 70 | $1,044,651 |
| VyvgartEfgartigimod Alfa-Fcab | 13 | $810,573 |
| NuplazidPimavanserin Tartrate | 108 | $540,133 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 20 | $330,660 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 30 | $251,887 |
| VumerityDiroximel Fumarate | 16 | $165,214 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 11 | $134,190 |
| IngrezzaValbenazine Tosylate | 12 | $97,452 |
| Kesimpta PenOfatumumab | 11 | $94,517 |
| AptiomEslicarbazepine Acetate | 67 | $87,002 |
| BriviactBrivaracetam | 82 | $84,666 |
| EpidiolexCannabidiol (Cbd) | 13 | $84,649 |
| InbrijaLevodopa | 23 | $79,102 |
| Aimovig AutoinjectorErenumab-Aooe | 91 | $73,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Trintellix | $136 | $1,680,473110 claims |
| Argenx US, Inc.Vyvgart | $902 | $810,57313 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,016 | $540,133108 claims |
| PfizerOctagam, Nurtec Odt, Eliquis | $1,730 | $410,065103 claims |
| Grifols USA, LLCGamunex-C | $566 | $251,88730 claims |
| BiogenVumerity | $2,280 | $165,21416 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $1,331 | $143,42863 claims |
| UCB, Inc.Briviact, Neupro | $3,571 | $119,708116 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $611 | $87,00267 claims |
| Acorda Therapeutics, IncInbrija | $12,812 | $79,10223 claims |
| AbbVieUbrelvy, Qulipta | $3,934 | $71,58172 claims |
| Kyowa Kirin, Inc.Nourianz | $495 | $69,83321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 neurology providers in Alabama.
Other neurology in Huntsville
- Harry McDarisHuntsville$307K
- Belinda Savage-EdwardsHuntsville$296K
- Anjaneyulu AlapatiHuntsville$133K
- Bhageeradh MulpurHuntsville$74K
- Scott HitchcockHuntsville$41K
- David WhiteHuntsville$40K
- Amit AroraHuntsville$22K
- Jitesh KarHuntsville$18K
- Diane CounceBirmingham$895K
- Daniel DeesMobile$799K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.